Plant Name: mammea siamensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| OPRD1; | |
| HTR2C; DRD3; | |
| GCGR; | |
| PTPN1; | |
| FLT3; PRKCG; MET; CAMK2B; BLK; BRSK1; MAP4K4; MAP3K20; FLT1; GSK3B; FER; CDK5; KIT; FGFR1; MAP4K2; CSNK2A1; SYK; JAK3; CLK4; NEK2; NTRK1; TTK; MARK3; HIPK4; ROCK2; TAOK1; HIPK2; GSK3A; IRAK4; FGFR3; FES; ERBB4; AURKB; DYRK1A; LYN; CDK2; MAPK9; FLT4; ROCK1; INSR; CAMK2D; CAMK2G; STK17A; RPS6KA3; SLK; PIM3; PIM2; PRKACA; PLK4; DAPK3; SGK2; MAPK8; CDC7; MKNK2; CDK1; MAPK1; MAPK14; CSNK1A1; PIM1; PHKG2; PBK; LCK; MAPK10; FRK; STK3; PRKD2; PRKD3; MATK; MINK1; PDPK1; MAPK11; ROS1; RPS6KB1; IGF1R; TYRO3; TYK2; NTRK3; NTRK2; NEK4; CSNK1G2; CSNK1G3; KDR; CHEK2; CLK2; RET; DYRK3; CHEK1; CSNK1D; CSF1R; MELK; EIF2AK2; | |
| ALOX5; | |
| CASP7; CASP1; | |
| BACE1; | |
| VCP; | |
| LMNA; MCL1; MAPT; THPO; | |
| BRD4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Bromodomain | BRD4 | Bromodomain-containing protein 4 | O60885 | CHEMBL1163125 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Endoplasmic reticular retrotranslocon family | VCP | Transitional endoplasmic reticulum ATPase | P55072 | CHEMBL1075145 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family B GPCR) | GCGR | Glucagon receptor | P47871 | CHEMBL1985 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | PRKCG | Protein kinase C gamma | P05129 | CHEMBL2938 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | BLK | Tyrosine-protein kinase BLK | P51451 | CHEMBL2250 |
| Protein Kinase | BRSK1 | BR serine/threonine-protein kinase 1 | Q8TDC3 | CHEMBL5650 |
| Protein Kinase | MAP4K4 | Mitogen-activated protein kinase kinase kinase kinase 4 | O95819 | CHEMBL6166 |
| Protein Kinase | MAP3K20 | Mixed lineage kinase 7 | Q9NYL2 | CHEMBL3886 |
| Protein Kinase | FLT1 | Vascular endothelial growth factor receptor 1 | P17948 | CHEMBL1868 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | FER | Tyrosine-protein kinase FER | P16591 | CHEMBL3982 |
| Protein Kinase | CDK5 | Cyclin-dependent kinase 5 | Q00535 | CHEMBL4036 |
| Protein Kinase | KIT | Stem cell growth factor receptor | P10721 | CHEMBL1936 |
| Protein Kinase | FGFR1 | Fibroblast growth factor receptor 1 | P11362 | CHEMBL3650 |
| Protein Kinase | MAP4K2 | Mitogen-activated protein kinase kinase kinase kinase 2 | Q12851 | CHEMBL5330 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | JAK3 | Tyrosine-protein kinase JAK3 | P52333 | CHEMBL2148 |
| Protein Kinase | CLK4 | Dual specificity protein kinase CLK4 | Q9HAZ1 | CHEMBL4203 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | NTRK1 | Nerve growth factor receptor Trk-A | P04629 | CHEMBL2815 |
| Protein Kinase | TTK | Dual specificity protein kinase TTK | P33981 | CHEMBL3983 |
| Protein Kinase | MARK3 | Serine/threonine-protein kinase c-TAK1 | P27448 | CHEMBL5600 |
| Protein Kinase | HIPK4 | Homeodomain-interacting protein kinase 4 | Q8NE63 | CHEMBL1075167 |
| Protein Kinase | ROCK2 | Rho-associated protein kinase 2 | O75116 | CHEMBL2973 |
| Protein Kinase | TAOK1 | Serine/threonine-protein kinase TAO1 | Q7L7X3 | CHEMBL5261 |
| Protein Kinase | HIPK2 | Homeodomain-interacting protein kinase 2 | Q9H2X6 | CHEMBL4576 |
| Protein Kinase | GSK3A | Glycogen synthase kinase-3 alpha | P49840 | CHEMBL2850 |
| Protein Kinase | IRAK4 | Interleukin-1 receptor-associated kinase 4 | Q9NWZ3 | CHEMBL3778 |
| Protein Kinase | FGFR3 | Fibroblast growth factor receptor 3 | P22607 | CHEMBL2742 |
| Protein Kinase | FES | Tyrosine-protein kinase FES | P07332 | CHEMBL5455 |
| Protein Kinase | ERBB4 | Receptor protein-tyrosine kinase erbB-4 | Q15303 | CHEMBL3009 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
| Protein Kinase | LYN | Tyrosine-protein kinase Lyn | P07948 | CHEMBL3905 |
| Protein Kinase | CDK2 | Cyclin-dependent kinase 2 | P24941 | CHEMBL301 |
| Protein Kinase | MAPK9 | c-Jun N-terminal kinase 2 | P45984 | CHEMBL4179 |
| Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
| Protein Kinase | ROCK1 | Rho-associated protein kinase 1 | Q13464 | CHEMBL3231 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | CAMK2D | CaM kinase II delta | Q13557 | CHEMBL2801 |
| Protein Kinase | CAMK2G | CaM kinase II gamma | Q13555 | CHEMBL3829 |
| Protein Kinase | STK17A | Serine/threonine-protein kinase 17A | Q9UEE5 | CHEMBL4525 |
| Protein Kinase | RPS6KA3 | Ribosomal protein S6 kinase alpha 3 | P51812 | CHEMBL2345 |
| Protein Kinase | SLK | Serine/threonine-protein kinase 2 | Q9H2G2 | CHEMBL4202 |
| Protein Kinase | PIM3 | Serine/threonine-protein kinase PIM3 | Q86V86 | CHEMBL5407 |
| Protein Kinase | PIM2 | Serine/threonine-protein kinase PIM2 | Q9P1W9 | CHEMBL4523 |
| Protein Kinase | PRKACA | cAMP-dependent protein kinase alpha-catalytic subunit | P17612 | CHEMBL4101 |
| Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
| Protein Kinase | DAPK3 | Death-associated protein kinase 3 | O43293 | CHEMBL2468 |
| Protein Kinase | SGK2 | Serine/threonine-protein kinase Sgk2 | Q9HBY8 | CHEMBL5794 |
| Protein Kinase | MAPK8 | c-Jun N-terminal kinase 1 | P45983 | CHEMBL2276 |
| Protein Kinase | CDC7 | Cell division cycle 7-related protein kinase | O00311 | CHEMBL5443 |
| Protein Kinase | MKNK2 | MAP kinase signal-integrating kinase 2 | Q9HBH9 | CHEMBL4204 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | CSNK1A1 | Casein kinase I alpha | P48729 | CHEMBL2793 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | PHKG2 | Phosphorylase kinase gamma subunit 2 | P15735 | CHEMBL2349 |
| Protein Kinase | PBK | PDZ-binding kinase | Q96KB5 | CHEMBL4896 |
| Protein Kinase | LCK | Tyrosine-protein kinase LCK | P06239 | CHEMBL258 |
| Protein Kinase | MAPK10 | c-Jun N-terminal kinase 3 | P53779 | CHEMBL2637 |
| Protein Kinase | FRK | Tyrosine-protein kinase FRK | P42685 | CHEMBL4223 |
| Protein Kinase | STK3 | Serine/threonine-protein kinase MST2 | Q13188 | CHEMBL4708 |
| Protein Kinase | PRKD2 | Serine/threonine-protein kinase D2 | Q9BZL6 | CHEMBL4900 |
| Protein Kinase | PRKD3 | Protein kinase C nu | O94806 | CHEMBL2595 |
| Protein Kinase | MATK | Tyrosine-protein kinase CTK | P42679 | CHEMBL4175 |
| Protein Kinase | MINK1 | Misshapen-like kinase 1 | Q8N4C8 | CHEMBL5518 |
| Protein Kinase | PDPK1 | 3-phosphoinositide dependent protein kinase-1 | O15530 | CHEMBL2534 |
| Protein Kinase | MAPK11 | MAP kinase p38 beta | Q15759 | CHEMBL3961 |
| Protein Kinase | ROS1 | Proto-oncogene tyrosine-protein kinase ROS | P08922 | CHEMBL5568 |
| Protein Kinase | RPS6KB1 | Ribosomal protein S6 kinase 1 | P23443 | CHEMBL4501 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | TYRO3 | Tyrosine-protein kinase receptor TYRO3 | Q06418 | CHEMBL5314 |
| Protein Kinase | TYK2 | Tyrosine-protein kinase TYK2 | P29597 | CHEMBL3553 |
| Protein Kinase | NTRK3 | NT-3 growth factor receptor | Q16288 | CHEMBL5608 |
| Protein Kinase | NTRK2 | Neurotrophic tyrosine kinase receptor type 2 | Q16620 | CHEMBL4898 |
| Protein Kinase | NEK4 | Serine/threonine-protein kinase Nek4 | P51957 | CHEMBL5819 |
| Protein Kinase | CSNK1G2 | Casein kinase I gamma 2 | P78368 | CHEMBL2543 |
| Protein Kinase | CSNK1G3 | Casein kinase I isoform gamma-3 | Q9Y6M4 | CHEMBL5084 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | CHEK2 | Serine/threonine-protein kinase Chk2 | O96017 | CHEMBL2527 |
| Protein Kinase | CLK2 | Dual specificity protein kinase CLK2 | P49760 | CHEMBL4225 |
| Protein Kinase | RET | Tyrosine-protein kinase receptor RET | P07949 | CHEMBL2041 |
| Protein Kinase | DYRK3 | Dual-specificity tyrosine-phosphorylation regulated kinase 3 | O43781 | CHEMBL4575 |
| Protein Kinase | CHEK1 | Serine/threonine-protein kinase Chk1 | O14757 | CHEMBL4630 |
| Protein Kinase | CSNK1D | Casein kinase I delta | P48730 | CHEMBL2828 |
| Protein Kinase | CSF1R | Macrophage colony stimulating factor receptor | P07333 | CHEMBL1844 |
| Protein Kinase | MELK | Maternal embryonic leucine zipper kinase | Q14680 | CHEMBL4578 |
| Protein Kinase | EIF2AK2 | Interferon-induced, double-stranded RNA-activated protein kinase | P19525 | CHEMBL5785 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005524; ATP binding | 6.877E-85 | 1.872E-81 | AURKB, BLK, BRSK1, CAMK2B, CAMK2D, CAMK2G, CDC7, CDK1, CDK2, CDK5, CHEK1, CHEK2, CLK2, CLK4, CSF1R, CSNK1A1, CSNK1D, CSNK1G2, CSNK1G3, CSNK2A1, DAPK3, DYRK1A, DYRK3, EIF2AK2, ERBB4, FER, FES, FGFR1, FGFR3, FLT1, FLT3, FLT4, FRK, GSK3A, GSK3B, HIPK2, HIPK4, IGF1R, INSR, IRAK4, JAK3, KDR, KIT, LCK, LYN, MAP3K20, MAP4K2, MAP4K4, MAPK1, MAPK10, MAPK11, MAPK14, MAPK8, MAPK9, MARK3, MATK, MELK, MET, MINK1, MKNK2, NEK2, NEK4, NTRK1, NTRK2, NTRK3, PBK, PDPK1, PHKG2, PIM1, PIM2, PIM3, PLK4, PRKACA, PRKCG, PRKD2, PRKD3, RET, ROCK1, ROCK2, ROS1, RPS6KA3, RPS6KB1, SGK2, SLK, STK17A, STK3, SYK, TAOK1, TTK, TYK2, TYRO3, VCP |
| CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 9.440E-12 | 1.168E-09 | BLK, FER, FES, FRK, JAK3, LCK, LYN, MATK, SYK, TYK2 |
| MF | GO:0003824; catalytic activity | GO:0050321; tau-protein kinase activity | 4.936E-11 | 5.748E-09 | BRSK1, CDK5, CSNK1D, GSK3A, GSK3B, PHKG2 |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 3.641E-10 | 3.925E-08 | AURKB, CDK2, CDK5, CHEK1, CHEK2, CSNK2A1, DYRK1A, DYRK3, HIPK2, HIPK4, MAPK11, MAPK14 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.558E-09 | 1.601E-07 | AURKB, CAMK2D, CSF1R, DRD3, HTR2C, KDR, LCK, LYN, MAP4K4, MAPK1, MAPK11, MAPK14, NEK2, PDPK1, PIM3, PRKACA, SYK |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 7.612E-09 | 7.176E-07 | ALOX5, AURKB, BRD4, BRSK1, CAMK2B, CAMK2D, CAMK2G, CASP7, CDC7, CDK1, CDK2, CDK5, CHEK1, CHEK2, CLK2, CSF1R, CSNK1D, CSNK2A1, DYRK1A, DYRK3, ERBB4, FRK, GSK3B, HIPK2, LMNA, MAPK1, MAPK10, MAPK11, MAPK14, MAPK8, MAPK9, MCL1, NEK2, PDPK1, PIM1, PRKACA, PRKD2, PRKD3, RPS6KA3, RPS6KB1, SGK2, VCP |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.480E-08 | 1.360E-06 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 3.439E-08 | 3.007E-06 | FLT1, FLT3, FLT4, KDR |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 9.459E-08 | 7.802E-06 | ERBB4, FGFR1, FLT1, FLT3, KDR, KIT, NTRK2 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.153E-07 | 1.634E-05 | ERBB4, FGFR1, FGFR3, INSR, KIT, LCK, MET, STK3, THPO |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 3.067E-07 | 2.264E-05 | ERBB4, FGFR1, FLT1, FLT4, IGF1R, INSR, LYN, NTRK1, NTRK2, NTRK3, RET, SYK |
| BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 4.839E-07 | 3.443E-05 | AURKB, CDK1, CDK2, CHEK1, HIPK4 |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 6.953E-07 | 4.746E-05 | FGFR3, FLT1, FLT3, KIT, LYN |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 7.648E-07 | 5.115E-05 | BACE1, CAMK2B, CAMK2D, CAMK2G, CDK5, CSNK1A1, CSNK1D, DRD3, FER, GSK3A, MAPK1, MAPK10, MAPK8, MAPK9, MAPT, MINK1, NTRK1, OPRD1, PDPK1, PRKACA, PRKCG, RET, ROCK1, RPS6KB1 |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 9.847E-07 | 6.344E-05 | BRSK1, CDK5, CHEK2, GSK3A, GSK3B, LCK, MAP4K2, MAPK1, MAPK14, PDPK1, PRKACA, PRKD2, PTPN1, RPS6KA3, SYK |
| BP | GO:0050896; response to stimulus | GO:0060397; JAK-STAT cascade involved in growth hormone signaling pathway | 1.295E-06 | 8.196E-05 | JAK3, LYN, MAPK1, PTPN1 |
| BP | GO:0008152; metabolic process | GO:0010506; regulation of autophagy | 1.442E-06 | 9.074E-05 | CASP1, CDK5, DAPK3, GSK3A, KDR, MAPK8, MAPT, MCL1, MET, PIM2, PRKACA |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 1.447E-06 | 9.081E-05 | CSNK1D, DRD3, MAPK10, MAPK8, MAPK9, PRKCG, ROCK2 |
| MF | GO:0098772; molecular function regulator | GO:0005088; Ras guanyl-nucleotide exchange factor activity | 1.604E-06 | 9.945E-05 | CAMK2B, CAMK2D, CAMK2G, ERBB4, FGFR1, FGFR3, JAK3, KIT, MET, RET |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.900E-06 | 1.153E-04 | CSF1R, ERBB4, FGFR3, FLT4, HTR2C, KDR, NTRK1, PRKD2, THPO |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.933E-06 | 1.166E-04 | CSF1R, DRD3, ERBB4, FGFR1, FGFR3, FLT1, FLT3, FLT4, GCGR, HTR2C, IGF1R, INSR, KDR, KIT, MET, NTRK1, NTRK2, NTRK3, OPRD1, RET, ROS1, TYRO3 |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 2.046E-06 | 1.217E-04 | ERBB4, FGFR1, FGFR3, KIT, LCK, MET |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 2.238E-06 | 1.317E-04 | AURKB, CDK1, CDK2, CHEK1 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 2.508E-06 | 1.468E-04 | CAMK2B, CAMK2D, CAMK2G, CHEK2, CSF1R, DAPK3, ERBB4, FGFR1, FLT3, FLT4, KIT, MAPT, MCL1, NTRK1, NTRK2, SLK, TTK |
| BP | GO:0008152; metabolic process | GO:0010628; positive regulation of gene expression | 3.131E-06 | 1.785E-04 | BRD4, CDK1, CDK2, CHEK1, CHEK2, DRD3, ERBB4, GSK3A, GSK3B, HIPK2, INSR, KIT, MAPK1, MAPK11, MAPK14, MAPK8, MAPK9, MET, NEK4, NTRK2, NTRK3, PIM2, PRKD2, RET, ROCK2, RPS6KA3, RPS6KB1 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.148E-06 | 1.790E-04 | LCK, LYN, MAPK1, PDPK1, PRKCG, SYK, TYRO3 |
| BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 5.473E-06 | 2.928E-04 | CAMK2B, CAMK2D, CAMK2G, GSK3B, MAPK1, MAPT |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 6.819E-06 | 3.535E-04 | BACE1, DAPK3, INSR, KDR, LCK, LYN, MAPK1, OPRD1, PRKACA, RET |
| BP | GO:0009987; cellular process | GO:2001020; regulation of response to DNA damage stimulus | 8.523E-06 | 4.283E-04 | CHEK1, CHEK2, DYRK1A, DYRK3, MAPT, MCL1, NEK4, PRKCG |
| BP | GO:0022610; biological adhesion | GO:0051893; regulation of focal adhesion assembly | 1.384E-05 | 6.712E-04 | DAPK3, KDR, ROCK1, ROCK2, SLK |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.579E-05 | 7.605E-04 | CDK5, GSK3B, IGF1R, NTRK1 |
| BP | GO:0050896; response to stimulus | GO:0009612; response to mechanical stimulus | 1.589E-05 | 7.605E-04 | CASP1, CHEK1, KIT, MAPK14, MAPK8, MAPK9, NTRK1, RPS6KB1 |
| BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 1.855E-05 | 8.685E-04 | BRD4, CDC7, CDK1, DRD3, FGFR1, INSR, RPS6KB1 |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 2.119E-05 | 9.774E-04 | IGF1R, INSR, LCK, TYRO3 |
| BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 2.168E-05 | 9.957E-04 | ERBB4, FGFR1, FGFR3, KIT, LCK, MET |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 2.255E-26 | 6.061E-24 | CAMK2B, CAMK2D, CAMK2G, CDK1, CDK5, CHEK1, CHEK2, CSNK2A1, DAPK3, DYRK1A, GSK3A, GSK3B, HIPK2, MAPK1, MAPK8, PDPK1, PHKG2, PRKD2, TTK |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.102E-25 | 1.292E-22 | BLK, ERBB4, FER, FES, FRK, IGF1R, INSR, JAK3, KDR, LCK, LYN, MATK, NTRK1, ROS1, SYK, TYK2 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.529E-05 | 1.135E-03 | CAMK2D, DRD3, HTR2C, KDR, LCK, LYN, PDPK1, PRKACA |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.782E-05 | 1.234E-03 | CYP1A2, MAPK1, MAPK8, MAPK9 |
| CC | GO:0032991; macromolecular complex | GO:0030877; beta-catenin destruction complex | 2.868E-05 | 1.267E-03 | CSNK1A1, GSK3A, GSK3B |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 3.189E-05 | 1.397E-03 | CASP1, KDR, MAPT, OPRD1, VCP |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 3.551E-05 | 1.522E-03 | CDK1, CDK2, FER, MAPK1, MAPK8, MAPK9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.808E-05 | 1.616E-03 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.808E-05 | 1.616E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.565E-05 | 1.915E-03 | AURKB, DRD3, MAPK1, MAPK11, MAPK14, NEK2, PDPK1, SYK |
| BP | GO:0051179; localization | GO:0034501; protein localization to kinetochore | 4.930E-05 | 2.041E-03 | AURKB, CDK1, TTK |
| MF | Unclassified; | GO:0004872; receptor activity | 5.606E-05 | 2.299E-03 | CSF1R, DRD3, ERBB4, FGFR1, FGFR3, FLT1, FLT3, FLT4, GCGR, HTR2C, IGF1R, INSR, KDR, KIT, MET, NTRK1, NTRK2, NTRK3, OPRD1, RET, ROS1, TYRO3 |
| BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 6.330E-05 | 2.557E-03 | CASP1, CASP7, ROCK1, TAOK1 |
| BP | GO:0022610; biological adhesion | GO:0045785; positive regulation of cell adhesion | 7.343E-05 | 2.930E-03 | GSK3B, JAK3, KDR, LCK, LYN, PDPK1, PRKD2, RET, ROCK1, SYK |
| MF | Unclassified; | GO:0004708; MAP kinase kinase activity | 7.779E-05 | 3.074E-03 | MAPK1, MAPK10, MAPK14 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 9.605E-05 | 3.689E-03 | CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004697; protein kinase C activity | 9.534E-05 | 3.689E-03 | PRKCG, PRKD2, PRKD3 |
| BP | GO:0009987; cellular process | GO:0032989; cellular component morphogenesis | 9.846E-05 | 3.768E-03 | BRSK1, CDK5, CSNK1A1, FER, MAP4K4, MAPK14, MET, MINK1, NTRK1, TYRO3 |
| BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 9.926E-05 | 3.785E-03 | CSNK1A1, CSNK1D, GSK3A, GSK3B, VCP |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 1.052E-04 | 3.964E-03 | CASP1, CASP7, LCK, MAPT, VCP |
| BP | GO:0009987; cellular process | GO:0038127; ERBB signaling pathway | 1.115E-04 | 4.185E-03 | ERBB4, FES, MAPK1, MATK, PDPK1 |
| CC | GO:0044464; cell part | GO:0030424; axon | 1.121E-04 | 4.201E-03 | BACE1, CDK5, MAPK1, MAPK8, MAPT, MINK1, NTRK1, RET |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 1.134E-04 | 4.243E-03 | KDR, MAPK14, PDPK1, PRKD2 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.153E-04 | 4.306E-03 | AURKB, MAPK1, NEK2 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.237E-04 | 4.595E-03 | BACE1, CSF1R, DRD3, FGFR1, FGFR3, FLT1, FLT3, FLT4, GCGR, HTR2C, IGF1R, INSR, KDR, MET, NTRK1, NTRK2, NTRK3, OPRD1, RET, TYRO3 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.239E-04 | 4.597E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| CC | GO:0043226; organelle | GO:0014069; postsynaptic density | 1.396E-04 | 5.059E-03 | CAMK2G, CDK5, LYN, MINK1, NTRK2, PDPK1, PRKCG |
| MF | GO:0005488; binding | GO:0019904; protein domain specific binding | 1.623E-04 | 5.805E-03 | CASP1, CDK2, CHEK1, DAPK3, DRD3, INSR, LCK, LYN, MAPT, MCL1, RPS6KB1, SYK, VCP |
| BP | GO:0032501; multicellular organismal process | GO:0035162; embryonic hemopoiesis | 1.629E-04 | 5.816E-03 | KDR, KIT, STK3 |
| BP | GO:0009987; cellular process | GO:1902532; negative regulation of intracellular signal transduction | 1.777E-04 | 6.323E-03 | DRD3, DYRK1A, DYRK3, GSK3A, IGF1R, LYN, MARK3, MCL1, MET, PBK, PTPN1 |
| BP | GO:0009987; cellular process | GO:0051129; negative regulation of cellular component organization | 1.881E-04 | 6.648E-03 | CDK5, CHEK1, GSK3B, LMNA, MAP4K4, MAPT, MET, NEK2, OPRD1, ROCK1, ROCK2, TTK |
| BP | GO:0009987; cellular process | GO:0007093; mitotic cell cycle checkpoint | 1.907E-04 | 6.700E-03 | AURKB, CDK1, CDK2, TAOK1, TTK |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.914E-04 | 6.700E-03 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 2.008E-04 | 6.995E-03 | CASP1, FLT3, LYN, MAPK14, MAPK8, NTRK3, RET, ROCK2, RPS6KB1 |
| BP | GO:0009987; cellular process | GO:0050857; positive regulation of antigen receptor-mediated signaling pathway | 2.218E-04 | 7.617E-03 | LCK, LYN, PRKD2 |
| BP | GO:0008152; metabolic process | GO:0031400; negative regulation of protein modification process | 2.527E-04 | 8.577E-03 | CDK1, CDK2, CDK5, IGF1R, LYN, NTRK3, PBK, PDPK1, PRKCG, PTPN1, ROCK1, ROCK2 |
| BP | GO:0032501; multicellular organismal process | GO:0033555; multicellular organismal response to stress | 2.529E-04 | 8.577E-03 | HTR2C, PRKCG, RET, RPS6KB1 |
| BP | GO:0008152; metabolic process | GO:0033138; positive regulation of peptidyl-serine phosphorylation | 2.555E-04 | 8.653E-03 | NTRK2, NTRK3, OPRD1, PRKD2, RET |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.929E-04 | 9.750E-03 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 1.268E-18 | 2.381E-16 | BLK, DYRK1A, EIF2AK2, FER, FES, FRK, JAK3, LCK, LYN, MATK, MELK, SYK, TYK2 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.600E-15 | 2.446E-13 | ALOX5, AURKB, BLK, BRD4, CAMK2B, CAMK2D, CAMK2G, CASP1, CASP7, CDK1, CDK2, CDK5, CHEK1, CSNK1A1, CSNK1D, CSNK1G2, CSNK2A1, DYRK3, EIF2AK2, ERBB4, FER, FES, FGFR1, FLT3, FRK, GSK3A, GSK3B, IRAK4, JAK3, LCK, LMNA, LYN, MAP3K20, MAPK1, MAPK10, MAPK11, MAPK14, MAPK8, MAPK9, MAPT, MARK3, MATK, MCL1, MINK1, NEK2, NTRK2, PDPK1, PHKG2, PIM1, PIM3, PLK4, PRKACA, PRKCG, PRKD2, PRKD3, PTPN1, RET, ROCK1, ROCK2, RPS6KA3, RPS6KB1, SGK2, STK3, SYK, TAOK1, TYK2, VCP |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 5.708E-15 | 8.512E-13 | ERBB4, INSR, KDR, KIT, LYN, SYK, TYRO3 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.271E-19 | 2.123E-17 | NTRK1; CAMK2B; GSK3B; NTRK2; CAMK2D; PDPK1; NTRK3; MATK; IRAK4; MAPK14; MAPK10; MAPK11; MAPK9; RPS6KA3; MAPK8; MAPK1; CAMK2G |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.772E-16 | 1.479E-14 | PRKCG; NTRK1; MAP4K2; NTRK2; MAPK14; STK3; MAPK10; MAPK11; MAPK9; RPS6KA3; MAPK8; TAOK1; MKNK2; MAPK1; MAPT; PRKACA; FGFR3; MAP4K4; FGFR1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.105E-15 | 6.151E-14 | PRKCG; CAMK2B; CAMK2D; ROCK1; ROCK2; PDPK1; MAPK14; IGF1R; MAPK11; RPS6KB1; ERBB4; KDR; MAPK1; PRKACA; MET; CAMK2G; FGFR1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.627E-14 | 1.295E-12 | CSF1R; GSK3B; FLT1; SYK; PDPK1; INSR; FLT4; IGF1R; RPS6KB1; KIT; CDK2; KDR; MAPK1; SGK2; JAK3; FGFR3; MET; FGFR1; MCL1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.808E-14 | 1.338E-12 | PRKCG; RET; NTRK1; CSF1R; GSK3B; ROCK1; ROCK2; FLT3; DAPK3; IGF1R; MAPK10; MAPK9; MAPK8; CDK2; KIT; MAPK1; PRKACA; MET; FGFR3; FGFR1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 3.876E-14 | 1.295E-12 | PRKCG; CSF1R; FLT1; INSR; FLT4; MAPK14; IGF1R; MAPK11; PRKD3; KIT; KDR; MAPK1; PRKD2; FGFR3; MET; FGFR1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.212E-13 | 2.892E-12 | PRKCG; CSF1R; FLT1; INSR; FLT4; IGF1R; MAPK10; MAPK9; MAPK8; KIT; KDR; MAPK1; PRKACA; FGFR3; MET; FGFR1 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 2.269E-13 | 4.736E-12 | MAPK10; PRKCG; NTRK1; CAMK2B; MAPK11; MAPK9; CAMK2D; MAPK8; HTR2C; MAPK14; PRKACA; CAMK2G |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.486E-13 | 5.822E-12 | LYN; GSK3B; SYK; CSNK2A1; EIF2AK2; TYK2; MAPK14; MAPK10; MAPK11; MAPK9; MAPK8; CDK2; CDK1; PRKACA; JAK3 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.819E-13 | 5.231E-12 | PRKCG; CAMK2B; GSK3B; GSK3A; CAMK2D; MAPK14; MAPK10; MAPK11; MAPK9; MAPK8; PRKACA; DRD3; CAMK2G |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.651E-12 | 2.507E-11 | MAPK10; PRKCG; CAMK2B; GSK3B; MAPK9; CAMK2D; MAPK8; RPS6KB1; ERBB4; MAPK1; CAMK2G |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 5.737E-12 | 7.984E-11 | PRKCG; GSK3B; FLT1; ROCK1; ROCK2; PDPK1; FLT4; IGF1R; MAPK10; MAPK9; MAPK8; KDR; MAPK1; MET |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 6.283E-12 | 8.071E-11 | MAPK10; MAPK11; MAPK9; RPS6KA3; MAPK8; CDK2; CDK1; MAPK1; MAPK14; PRKACA; IGF1R |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 9.138E-12 | 1.090E-10 | MAPK10; PLK4; MAPK11; MAPK9; MAPK8; PDPK1; INSR; CDK2; MAPK1; MAPK14; SGK2; IGF1R |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.990E-11 | 2.077E-10 | MAPK10; PRKCG; CAMK2B; GSK3B; MAPK9; CAMK2D; MAPK8; CSNK2A1; ROCK2; CSNK1A1; PRKACA; CAMK2G |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.545E-11 | 1.720E-10 | MAPK10; PTPN1; GSK3B; MAPK9; MAPK8; RPS6KB1; PDPK1; INSR; MKNK2; PHKG2; MAPK1; PRKACA |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 7.400E-11 | 6.865E-10 | MAPK10; CAMK2B; MAPK11; MAPK9; CAMK2D; MAPK8; MAPK1; MAPK14; PRKACA; CAMK2G |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.888E-11 | 5.784E-10 | MAPK10; PRKCG; OPRD1; MAPK11; MAPK9; MAPK8; ROCK1; ROCK2; PDPK1; MAPK1; MAPK14 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.242E-10 | 1.037E-09 | LYN; MAPK10; MAPK11; MAPK9; MAPK8; SYK; PDPK1; MAPK1; MAPK14 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.082E-10 | 9.512E-10 | RET; NTRK1; FLT3; NTRK3; KIT; MAPK1; MET; FGFR3; FGFR1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.571E-10 | 2.045E-09 | PRKCG; CAMK2B; CAMK2D; FLT1; RPS6KB1; INSR; MKNK2; MAPK1; CAMK2G; IGF1R |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 9.920E-10 | 7.203E-09 | MAPK10; MAPK11; MAPK9; MAPK8; PDPK1; ALOX5; MAPK1; IRAK4; TYK2; MAPK14 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.493E-09 | 9.971E-09 | CAMK2B; RPS6KA3; CAMK2D; SLK; CDK2; CDK1; MAPK1; PRKACA; CAMK2G; IGF1R |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.383E-09 | 1.948E-08 | MAPK10; MAPK11; GSK3B; MAPK9; MAPK8; CASP1; EIF2AK2; MAPK1; IRAK4; TYK2; MAPK14 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.980E-09 | 1.843E-08 | MAPK10; MAPK11; CSF1R; MAPK9; MAPK8; SYK; LCK; MAPK1; TYK2; MAPK14 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.065E-10 | 2.327E-09 | MAPK10; MAPK11; MAPK9; CASP7; MAPK8; CASP1; MAPK1; IRAK4; MAPK14 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.208E-09 | 1.913E-08 | MAPK10; MAPK11; GSK3B; MAPK9; MAPK8; PDPK1; EIF2AK2; MAPK1; TYK2; MAPK14 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.067E-09 | 7.427E-09 | MAPK10; MAPK11; MAPK9; MAPK8; ROCK1; ROCK2; CASP1; MAPK1; MAPK14 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 4.045E-09 | 2.252E-08 | MAPK10; CAMK2B; MAPK11; MAPK9; CAMK2D; MAPK8; SYK; MAPK1; IRAK4; MAPK14; CAMK2G |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 8.912E-09 | 4.651E-08 | MAPK10; PTPN1; GSK3B; MAPK9; RPS6KA3; MAPK8; RPS6KB1; PDPK1; INSR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.948E-08 | 3.687E-07 | MAPK10; NTRK1; MAPK9; CASP7; MAPK8; PDPK1; LMNA; MAPK1; MCL1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 2.517E-09 | 1.617E-08 | MAPK10; MAPK11; MAPK9; MAPK8; ROCK1; ROCK2; MAPK1; MAPK14 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 7.216E-09 | 3.887E-08 | PTPN1; FER; CSNK2A1; INSR; MAPK1; MET; FGFR1; IGF1R |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 7.917E-08 | 3.687E-07 | PRKCG; CAMK2B; GSK3B; CAMK2D; KIT; MAPK1; PRKACA; CAMK2G |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.500E-07 | 6.264E-07 | MAPK10; CAMK2B; MAPK9; CAMK2D; MAPK8; ROCK1; ROCK2; MAPK1; PRKACA; CAMK2G |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 8.559E-08 | 3.863E-07 | MAPK10; PRKCG; MAPK11; MAPK9; MAPK8; MAPK1; MAPK14; PRKACA |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 3.707E-07 | 1.440E-06 | LYN; MAPK11; ROCK1; SYK; ROCK2; MAPK1; MAPK14; PRKACA |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 7.484E-08 | 3.676E-07 | PRKCG; CAMK2B; RPS6KA3; CAMK2D; MAPK1; PRKACA; CAMK2G |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.378E-07 | 5.900E-07 | MAPK10; MAPK11; GSK3B; MAPK9; MAPK8; MAPK1; MAPK14 |
| hsa04925 | Aldosterone synthesis and secretion_Homo sapiens_hsa04925 | 3.123E-07 | 1.252E-06 | PRKCG; CAMK2B; CAMK2D; PRKD3; PRKD2; PRKACA; CAMK2G |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.412E-06 | 5.016E-06 | MAPK10; MAPK11; MAPK9; MAPK8; PIM1; MAPK1; MAPK14 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.680E-06 | 5.633E-06 | RET; NTRK1; CSF1R; FLT1; ERBB4; KIT; KDR; FGFR3; MET; IGF1R |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.179E-06 | 4.377E-06 | MAPK11; GSK3B; MAPK1; MAPK14; FGFR3; JAK3; FGFR1; IGF1R |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 9.233E-08 | 4.058E-07 | LYN; MAPK10; MAPK11; MAPK9; MAPK8; MAPK14; MET |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.646E-08 | 1.339E-07 | MAPK10; MAPK11; MAPK9; MAPK8; CASP1; MAPK1; MAPK14 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.991E-06 | 6.272E-06 | LYN; SYK; CHEK1; CDK2; CDK1; EIF2AK2; MAPK1; PRKACA; JAK3 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.412E-06 | 5.016E-06 | MAPK10; PRKCG; MAPK9; MAPK8; RPS6KB1; PDPK1; MAPK1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.631E-06 | 7.988E-06 | PRKCG; CAMK2B; CAMK2D; ROCK1; ROCK2; MAPK1; PRKACA; CAMK2G |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.720E-06 | 5.633E-06 | MAPK11; GSK3B; MAPK9; PDPK1; LCK; MAPK1; MAPK14 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.956E-06 | 6.272E-06 | MAPK10; MAPK11; MAPK9; MAPK8; MAPK1; IRAK4; MAPK14 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.508E-06 | 7.756E-06 | MAPK10; MAPK11; MAPK9; CASP7; MAPK8; MAPK1; MAPK14 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.720E-06 | 5.633E-06 | MAPK10; MAPK11; MAPK9; MAPK8; MAPK1; IRAK4; MAPK14 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 6.909E-06 | 1.923E-05 | PRKCG; CAMK2B; CAMK2D; ERBB4; PHKG2; HTR2C; PRKACA; CAMK2G |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.830E-06 | 8.439E-06 | PRKCG; CYP2D6; ALOX5; HTR2C; MAPK1; CYP2C19; PRKACA |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.531E-06 | 5.326E-06 | PRKCG; CAMK2B; CAMK2D; MAPK1; CAMK2G; IGF1R |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 8.446E-06 | 2.312E-05 | MAPK10; MAPK9; MAPK8; CSNK2A1; CDK2; CDK1; EIF2AK2; TYK2 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 5.570E-06 | 1.632E-05 | GSK3B; CHEK2; CHEK1; CDK2; CDK1; CDC7; TTK |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.969E-07 | 2.645E-06 | RPS6KB1; FLT3; KIT; PIM1; MAPK1; PIM2 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 9.136E-06 | 2.422E-05 | LYN; GSK3B; GSK3A; ROCK1; ROCK2; MAPK1; PRKACA; JAK3 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 6.524E-06 | 1.847E-05 | GSK3B; ROCK1; CDK5; ROCK2; FES; MAPK1; MET |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.023E-05 | 2.629E-05 | GSK3B; CSNK2A1; CDK2; EIF2AK2; IRAK4; TYK2; JAK3 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.775E-05 | 4.424E-05 | CAMK2B; MAPK11; CAMK2D; MAPK1; MAPK14; PRKACA; CAMK2G |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.021E-05 | 4.822E-05 | MAPK10; GSK3B; MAPK9; GSK3A; CASP7; MAPK8; INSR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 9.678E-06 | 2.525E-05 | GSK3B; PDPK1; CDK2; MAPK1; FGFR1; IGF1R |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 1.409E-05 | 3.566E-05 | PRKCG; CAMK2B; CAMK2D; MAPK1; PRKACA; CAMK2G |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.001E-05 | 4.822E-05 | CAMK2B; CAMK2D; GCGR; PHKG2; PRKACA; CAMK2G |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.092E-04 | 2.308E-04 | CSF1R; FLT1; THPO; FLT3; FLT4; KIT; KDR; MET |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 9.066E-06 | 2.422E-05 | PRKCG; CDK1; HTR2C; MAPK1; CSNK1D; PRKACA |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.420E-05 | 7.717E-05 | PRKCG; CAMK2B; CAMK2D; MAPK1; PRKACA; CAMK2G |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.567E-04 | 3.272E-04 | MAPK10; PRKCG; MAPK9; MAPK8; CDK2; MAPK1 |
| hsa04340 | Hedgehog signaling pathway_Homo sapiens_hsa04340 | 3.149E-07 | 1.252E-06 | GSK3B; CSNK1G3; CSNK1A1; CSNK1D; PRKACA; CSNK1G2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.347E-04 | 6.575E-04 | BACE1; GSK3B; CASP7; CDK5; MAPK1; MAPT |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 4.830E-04 | 9.104E-04 | NTRK1; CSF1R; FLT1; FLT3; MET; IGF1R |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 5.639E-04 | 9.895E-04 | GSK3B; MAPK8; LCK; CHEK2; CHEK1; PRKACA; JAK3 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.283E-03 | 2.142E-03 | PRKCG; ROCK1; PIM1; MAPK1; FGFR3; MET; MCL1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.907E-04 | 9.104E-04 | PRKCG; GSK3B; PDPK1; MAPK1; PRKACA |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.625E-04 | 3.303E-04 | LYN; PRKCG; SYK; RPS6KB1; MAPK1 |
| hsa04141 | Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | 2.434E-03 | 3.834E-03 | MAPK10; MAPK9; VCP; MAPK8; EIF2AK2 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 4.907E-04 | 9.104E-04 | PRKCG; MAPK11; ROCK1; ROCK2; MAPK14 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 6.610E-03 | 9.769E-03 | ROCK1; ROCK2; MAPK1; FGFR3; FGFR1 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 5.298E-04 | 9.571E-04 | PRKCG; ROCK1; ROCK2; MAPK1; PRKACA |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.815E-03 | 2.915E-03 | THPO; PIM1; TYK2; JAK3; MCL1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.625E-04 | 3.303E-04 | LYN; SYK; CSNK2A1; LCK; IRAK4 |
| hsa04911 | Insulin secretion_Homo sapiens_hsa04911 | 1.062E-04 | 2.273E-04 | PRKCG; CAMK2B; CAMK2D; PRKACA; CAMK2G |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.311E-03 | 3.676E-03 | OPRD1; ROCK1; ROCK2; INSR; MAPK1 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 6.604E-03 | 9.769E-03 | PRKCG; SYK; LCK; MAPK1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 8.257E-03 | 1.189E-02 | SYK; INSR; KIT; MAPK1 |
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 2.506E-02 | 3.459E-02 | PRKCG; MAPK1; PRKACA |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 4.901E-03 | 7.374E-03 | RPS6KB1; PDPK1; INSR; IGF1R |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 5.470E-05 | 1.202E-04 | PRKCG; CAMK2B; CAMK2D; PRKACA; CAMK2G |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.971E-05 | 4.822E-05 | PRKCG; RPS6KA3; RPS6KB1; PDPK1; MAPK1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.806E-03 | 2.915E-03 | RPS6KB1; INSR; PRKACA; IGF1R |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 3.381E-05 | 7.717E-05 | PRKCG; CAMK2B; CAMK2D; PRKACA; CAMK2G |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.138E-05 | 5.029E-05 | PRKCG; MAPK11; KDR; MAPK1; MAPK14 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.417E-03 | 2.342E-03 | CSF1R; THPO; FLT3; KIT |
| hsa04350 | TGF-beta signaling pathway_Homo sapiens_hsa04350 | 1.117E-02 | 1.581E-02 | ROCK1; RPS6KB1; MAPK1 |
| hsa04622 | RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | 4.182E-05 | 9.313E-05 | MAPK10; MAPK11; MAPK9; MAPK8; MAPK14 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.047E-02 | 1.494E-02 | CYP1A2; CYP3A4; CYP2C19 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.316E-05 | 5.371E-05 | MAPK10; GSK3B; MAPK9; MAPK8; MAPK1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.802E-04 | 9.104E-04 | MAPK10; MAPK9; MAPK8; MAPK1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 6.514E-06 | 1.847E-05 | MAPK10; MAPK9; MAPK8; INSR; MAPK1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 7.042E-04 | 1.188E-03 | LYN; GSK3B; SYK; MAPK1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 4.270E-04 | 8.291E-04 | RPS6KB1; INSR; PRKACA; IGF1R |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 6.339E-04 | 1.091E-03 | MAPK1; MET; FGFR1; IGF1R |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.616E-03 | 1.106E-02 | CYP2D6; CYP1A2; CYP3A4 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 3.332E-04 | 6.575E-04 | LYN; PRKCG; MAPK1; IGF1R |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 6.783E-03 | 9.937E-03 | MAPK10; MAPK9; MAPK8 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 7.042E-04 | 1.188E-03 | MAPK11; MAPK1; IRAK4; MAPK14 |
| hsa05130 | Pathogenic Escherichia coli infection_Homo sapiens_hsa05130 | 3.685E-02 | 4.923E-02 | ROCK1; ROCK2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.688E-04 | 9.895E-04 | CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 5.688E-04 | 9.895E-04 | CHEK2; CDK2; CHEK1; CDK1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.980E-02 | 4.014E-02 | CDK5; PRKACA |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | 2.759E-02 | 3.746E-02 | PRKCG; PRKACA |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.631E-03 | 5.512E-03 | PRKCG; PDPK1; MAPK1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 3.450E-03 | 5.286E-03 | CASP7; VCP; CASP1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.941E-03 | 4.548E-03 | GSK3B; PDPK1; MAPK1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.642E-04 | 3.303E-04 | ALOX5; INSR; PRKACA; IGF1R |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 2.783E-03 | 4.343E-03 | MAPK11; CASP1; MAPK14 |
| hsa05340 | Primary immunodeficiency_Homo sapiens_hsa05340 | 1.761E-02 | 2.451E-02 | LCK; JAK3 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 6.142E-05 | 1.332E-04 | PRKCG; PDPK1; INSR; MAPK1 |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.585E-02 | 2.224E-02 | MAPK1; PRKACA |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.482E-03 | 2.427E-03 | DAPK3; MAPK1; FGFR3 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.330E-04 | 9.571E-04 | NTRK1; RET; MAPK1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.330E-04 | 9.571E-04 | CYP1A2; CYP3A4; CYP2C19 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.720E-02 | 3.724E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | RPS6KB1 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | FLT1 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; PTPN1; PTPN1; GCGR; GCGR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; GCGR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| H00-H59: Diseases of the eye and adnexa | Neovascular age-related macular degeneration | H35.3 | FLT1 |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | FLT1 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
| NA: NA | Primary insomnia | NA | HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5; NTRK1; MAPK14 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | INSR; OPRD1; NTRK1; ROCK1; CDK1; HTR2C; IGF1R |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; FLT1; KDR; CHEK1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | BRD4; KDR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; DRD3 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | ROCK1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | FLT1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; ERBB4; CDK2; KDR; IGF1R; IGF1R; CHEK1; CHEK1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HTR2C; HTR2C; GCGR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; MAPK8; NTRK2; RET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; GCGR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| C00-D49: Neoplasms | Renal cancer | C64 | FLT1; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; GCGR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; KDR; IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; MAPK14 |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| C00-D49: Neoplasms | Multiple myeloma | C90 | VCP; PIM2; FGFR3; IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2C |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| H00-H59: Diseases of the eye and adnexa | Exudative age-related macular degeneration | H35.3 | FLT1 |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; GSK3A; AURKB |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| C00-D49: Neoplasms | Mesothelioma | C45 | MARK3 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; KDR; KDR; KDR |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| NA: NA | Metastatic hormone refractory prostate cancer | NA | LYN |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; MET; NTRK3; SYK; MELK; NTRK1; PIM2; FGFR3; ERBB4; AURKB; CDK2; FLT4; KDR; KDR; KDR; MAPK8; MAPK1; ROS1; IGF1R; FGFR1; KIT; CHEK2; RET; CHEK1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| C00-D49: Neoplasms | Advanced or metastatic renal cell cancer | C64 | FGFR3 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; HTR2C; HTR2C |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| I00-I99: Diseases of the circulatory system | Peripheral arterial occlusive disease | I73.9 | FGFR1 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| C00-D49: Neoplasms | Advanced solid malignancies | D10-D36, D3A | NTRK1 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; GSK3A; HTR2C |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; RET |
| C00-D49: Neoplasms | Thymoma | C37, D15.0 | CDK2 |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; KDR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; MAPT; NTRK1; FGFR3; BRD4; GSK3B |
| C00-D49: Neoplasms | ALK-positive advanced or metastatic NSCLC | C33, C34 | ROS1 |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| P00-P96: Certain conditions originating in the perinatal period | Central nervous system injury | P11.9 | MAPK10 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; FLT1; BRD4; CHEK1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; CDK2 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | FLT1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; PDPK1; FGFR1; CHEK1 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| NA: NA | GIST | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; OPRD1; CAMK2D; CAMK2G; HTR2C; CYP3A4 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | MAPK14 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; PIM2; ROCK1; MAPK14; IRAK4; KIT |
| NA: NA | Inflammatory diseases | NA | MAPK14 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; FLT4 |
| C00-D49: Neoplasms | Acute promyelocytic leukemia | C92.4 | GSK3A |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; ROCK1; MAPK14 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; LYN |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; BRD4; ROCK1 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Bone disease | M00-M99 | LYN |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | MAPK8 |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; INSR; KDR; KDR; KDR; CDK1; IGF1R |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; SYK; LCK |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | FLT1 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ROCK1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | FGFR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; PTPN1; GSK3B; HTR2C; GCGR; GCGR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ROCK1 |
| I00-I99: Diseases of the circulatory system | Hereditary hemorrhagic telangiectasia | I78.0 | FLT1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | FLT3; FLT3; MET; FLT1; MCL1; CSNK2A1; SYK; TTK; FGFR3; ERBB4; BRD4; CDK2; FLT4; ROCK1; GSK3B; KDR; MAPK9; CDK1; MAPK1; MAPK14; PIM1; PDPK1; RPS6KB1; IGF1R; FGFR1; KIT; CHEK2; RET; CHEK1 |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; DRD3 |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; AURKB; CDC7 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; FGFR3; FLT4; KDR; IGF1R |
| I00-I99: Diseases of the circulatory system | Severe coronary heart disease | I25.1 | FGFR1 |
| NA: NA | Rheumatold arthritis | NA | MAPK14 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Retinoblastoma | C69.2 | FGFR3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; ALOX5; SYK; CASP1; OPRD1; ROCK2; CAMK2D; CAMK2G; MAPK14 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1; GSK3A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2C; DRD3 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3 |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | FGFR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |